Circulating Vitamin D Level and Its Impact on Mortality and Recurrence in Stage III Colorectal Cancer Patients: A Systematic Review and Meta-Analysis.
colorectal cancer
disease-free survival
prognosis
survival
vitamin D
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 May 2023
31 May 2023
Historique:
received:
08
05
2023
revised:
30
05
2023
accepted:
30
05
2023
medline:
10
6
2023
pubmed:
10
6
2023
entrez:
10
6
2023
Statut:
epublish
Résumé
Vitamin D (VD) has been implicated in several diseases, including colorectal cancer (CRC). This study aimed to determine whether there is an association between VD levels and time-to-outcome in stage III CRC patients through a systematic review and meta-analysis. The study adhered to the PRISMA 2020 statement. Articles were searched in PubMed/MEDLINE and Scopus/ELSEVIER. Four articles were selected, with the primary objective of providing a pooled estimate of the risk of death specifically in stage III CRC patients based on pre-operative VD levels. Study heterogeneity and publication bias were analyzed using Tau The selected studies showed significant heterogeneity regarding time-to-outcome, technical assessments, and serum VD concentration measures. The pooled analysis of 2628 and 2024 patients revealed a 38% and 13% increase in the risk of death (HR: 1.38, 95% CI: 0.71-2.71) and recurrence (HR: 1.13; 95% CI: 0.84-1.53), respectively, for random-effects models among patients with lower levels of VD. Our findings suggest that a low concentration of VD has a significant negative impact on time-to-outcome in stage III CRC.
Sections du résumé
BACKGROUND
BACKGROUND
Vitamin D (VD) has been implicated in several diseases, including colorectal cancer (CRC). This study aimed to determine whether there is an association between VD levels and time-to-outcome in stage III CRC patients through a systematic review and meta-analysis.
METHODS
METHODS
The study adhered to the PRISMA 2020 statement. Articles were searched in PubMed/MEDLINE and Scopus/ELSEVIER. Four articles were selected, with the primary objective of providing a pooled estimate of the risk of death specifically in stage III CRC patients based on pre-operative VD levels. Study heterogeneity and publication bias were analyzed using Tau
RESULTS
RESULTS
The selected studies showed significant heterogeneity regarding time-to-outcome, technical assessments, and serum VD concentration measures. The pooled analysis of 2628 and 2024 patients revealed a 38% and 13% increase in the risk of death (HR: 1.38, 95% CI: 0.71-2.71) and recurrence (HR: 1.13; 95% CI: 0.84-1.53), respectively, for random-effects models among patients with lower levels of VD.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that a low concentration of VD has a significant negative impact on time-to-outcome in stage III CRC.
Identifiants
pubmed: 37296974
pii: cancers15113012
doi: 10.3390/cancers15113012
pmc: PMC10251929
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Curr Oncol. 2019 Nov;26(Suppl 1):S43-S52
pubmed: 31819709
Front Oncol. 2022 Dec 07;12:1024467
pubmed: 36568209
Cancer Treat Rev. 2019 May;75:1-11
pubmed: 30849607
Eur J Epidemiol. 2017 Nov;32(11):961-971
pubmed: 28884317
Acta Oncol. 2016 Dec;55(12):1425-1433
pubmed: 27435662
Nutrients. 2020 Jul 15;12(7):
pubmed: 32679784
Semin Cancer Biol. 2022 Feb;79:217-230
pubmed: 32485310
Nutrients. 2023 Jan 17;15(3):
pubmed: 36771187
Pharmacol Ther. 2022 Sep;237:108252
pubmed: 35926664
Clin Cancer Res. 2006 May 1;12(9):2795-803
pubmed: 16675573
Nutrients. 2023 Jan 13;15(2):
pubmed: 36678292
Front Oncol. 2020 Dec 17;10:581597
pubmed: 33392078
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
BMJ Open. 2019 Dec 23;9(12):e030513
pubmed: 31874870
Br J Cancer. 2012 Jun 26;107(1):158-60
pubmed: 22588559
Cancer Causes Control. 2022 Feb;33(2):167-182
pubmed: 34708323
Adv Exp Med Biol. 2018;1108:13-23
pubmed: 30143987
FASEB J. 2022 Jan;36(1):e22082
pubmed: 34918389
Cell Signal. 2022 Aug;96:110355
pubmed: 35595176
Med Oncol. 2022 Oct 29;40(1):2
pubmed: 36308576
Crit Rev Oncol Hematol. 2022 Jan;169:103537
pubmed: 34801698
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Cochrane Database Syst Rev. 2023 Jan 27;1:CD012664
pubmed: 36705288
ANZ J Surg. 2003 Sep;73(9):712-6
pubmed: 12956787
Cancer. 2014 Dec 1;120 Suppl 23:3793-806
pubmed: 25412391
J Clin Oncol. 2014 Aug 10;32(23):2430-9
pubmed: 25002714
Crit Rev Oncol Hematol. 2017 Apr;112:190-197
pubmed: 28325259
Epigenomics. 2022 Oct;14(19):1213-1228
pubmed: 36325830
JNCI Cancer Spectr. 2021 Jul 23;5(5):
pubmed: 34485815
J Clin Oncol. 2011 Feb 1;29(4):e81-2
pubmed: 21060025
Oncol Rep. 2014 Aug;32(2):491-504
pubmed: 24919507
Antioxidants (Basel). 2022 May 30;11(6):
pubmed: 35739987
Nutrients. 2018 Jul 13;10(7):
pubmed: 30011816
In Vivo. 2023 Jan-Feb;37(1):286-293
pubmed: 36593062
Nutrients. 2020 Jun 17;12(6):
pubmed: 32560347
J Nutr Sci Vitaminol (Tokyo). 2018;64(6):432-444
pubmed: 30606966
EBioMedicine. 2018 May;31:11-12
pubmed: 29724656
Br J Cancer. 2017 Apr 11;116(8):1092-1110
pubmed: 28301870
Mol Ther. 2021 Feb 3;29(2):587-596
pubmed: 33333293
Cancer Treat Rev. 2020 Aug;88:102059
pubmed: 32622273
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
BMC Med Res Methodol. 2014 Feb 18;14:25
pubmed: 24548571
Nutrients. 2022 Oct 06;14(19):
pubmed: 36235800
Life Sci. 2022 May 1;296:120442
pubmed: 35245520
ESMO Open. 2021 Aug;6(4):100184
pubmed: 34237612
Nutrients. 2021 Jan 06;13(1):
pubmed: 33419149